M&T Bank’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

M&T Bank’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-4,120	Closed	-$415K	–	1632
2021 Q3	$415K	Sell	4,120 -43	-1%	-$5.04K	﹤0.01%	1090
2021 Q2	$589K	Sell	4,163 -424	-9%	-$47.9K	﹤0.01%	956
2021 Q1	$457K	Sell	4,587 -1,247	-21%	-$145K	﹤0.01%	1041
2020 Q4	$721K	Buy	5,834 +57	+1%	+$7.49K	﹤0.01%	896
2020 Q3	$562K	Sell	5,777 -375	-6%	-$46.9K	﹤0.01%	925
2020 Q2	$960K	Buy	6,152 +2,902	+89%	+$441K	0.01%	695
2020 Q1	$469K	Sell	3,250 -250	-7%	-$48.3K	﹤0.01%	933
2019 Q4	$716K	Hold	3,500	–	–	﹤0.01%	728
2019 Q3	$281K	Sell	3,500 -9	-0.3%	-$764	﹤0.01%	1242
2019 Q2	$331K	Buy	3,509 +250	+8%	+$21.6K	﹤0.01%	1175
2019 Q1	$279K	Buy	+3,259	New	+$271K	﹤0.01%	1244
2018 Q4	–	Sell	-2,500	Closed	-$204K	–	1588
2018 Q3	$204K	Buy	+2,500	New	+$176K	﹤0.01%	1427

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

M&T Bank's RETA Position: Q4 2021 in Review

M&T Bank sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2021, closing a stake of 4,120 shares — an estimated $415K sold.

M&T Bank first reported a position in RETA in Q3 2018 and held it in 12 quarters. The position peaked at $960K in Q2 2020. 151 funds tracked by Wall St. Rank hold RETA as of Q4 2021.

M&T Bank reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2021 after selling out during the quarter.
M&T Bank sold 4,120 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2021, an estimated $415K.
M&T Bank first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2018 and held it in 12 quarters.
M&T Bank's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $960K in Q2 2020.
151 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2021.

Based on M&T Bank's 13F filing for Q4 2021, filed 7 Feb 2022.